News | Magnetic Resonance Imaging (MRI) | April 13, 2016

Study will seek to identify early indicators of brain trauma using MRI

UC Irvine study, UCI, Toshiba, high school football players, cerebral microbleeds, CMB

April 13, 2016 — As chronic traumatic encephalopathy (CTE) stands in the national spotlight for high impact sports, the University of California, Irvine has partnered with Toshiba America Medical Systems Inc. for a first-of-its-kind study of cerebral microbleeds (CMB) in high school football players as a potential precursor to CTE. The study will utilize Toshiba’s Vantage Titan 3T magnetic resonance (MR) system as the key diagnostic tool, taking advantage of its non-invasive capabilities.

The study will investigate the use of non-contrast MRI as a safe and noninvasive way to examine youth athletes and other patients for early signs of CTE, a degenerative disease found in those who suffer head trauma and a well-documented consequence of sub-concussive head injury. This will include evaluations of local high school student volunteers, including 100 test subjects (football players) and 50 control subjects (non-football players). Toshiba will provide application training to UCI researchers concerning the use of Toshiba’s MRI equipment.

“There have not been extensive studies of CTE in younger populations to date, so we see this as an important opportunity to examine if there are precursors or early signs that can lead to better diagnosis and treatment,” said Mark Fisher, M.D., UCI professor of neurology and study lead researcher. “Using Toshiba’s Titan 3T MR system, we may have an effective way to examine how playing football is affecting these subjects, and we hope to break new ground in diagnosing and treating head trauma before it can potentially cause problems for these athletes in the future.”

The Vantage Titan 3T MR was chosen for its ability to provide non-contrast neuro imaging. This includes elements such as a suite of advanced neuro-imaging sequences and Pianissimo noise-reduction technology, and in particular its ability to determine the prevalence of CMB using the Flow Sensitive Black Blood (FSBB) sequence.

For more information: www.uci.edu


Related Content

News | Radiology Business

July 25, 2024 — Immunis, Inc., a clinical-stage biotech developing groundbreaking secretome therapeutics for age and ...

Time July 25, 2024
arrow
News | RSNA

July 23, 2024 — Professional registration is open for RSNA 2024, the world’s largest radiology forum. This year’s theme ...

Time July 23, 2024
arrow
News | Artificial Intelligence

July 23, 2024 — Researchers at the National Institutes of Health (NIH) found that an artificial intelligence (AI) model ...

Time July 23, 2024
arrow
News | Artificial Intelligence

July 17, 2024 — Hyperfine, a groundbreaking medical device company that has redefined brain imaging with the world’s ...

Time July 17, 2024
arrow
News | Prostate Cancer

July 11, 2024 — GE HealthCare’s MIM Software, a global provider of medical imaging analysis and artificial intelligence ...

Time July 11, 2024
arrow
News | Prostate Cancer

July 2, 2024 — A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, “Deep learning ...

Time July 02, 2024
arrow
News | Clinical Trials

June 27, 2024 — Prenuvo, which makes whole-body MRI screening for early cancer detection and other diseases, has ...

Time June 27, 2024
arrow
News | Pediatric Imaging

June 25, 2024 — Rady Children’s Hospital-San Diego, one of the nation’s top pediatric health care systems, today ...

Time June 25, 2024
arrow
News | MRI Breast

June 12, 2024 — Royal Philips recently announced the 1,111th installation of its revolutionary BlueSeal 1.5T magnet ...

Time June 12, 2024
arrow
News | Neuro Imaging

June 12, 2024 — Brainet, a developer of cutting-edge diagnostic tools for assessing brain health, and SimonMed Imaging ...

Time June 12, 2024
arrow
Subscribe Now